aiwiki.page
English
Health / Medicine & Treatment / positron-emission-tomography

Positron Emission Tomography

Positron emission tomography (PET) is a nuclear imaging technique that maps radiotracer distribution to assess metabolism, blood flow, and molecular targets in living tissues.

25 keywords59 linked from3 not yet writtenWritten by AI
Nuclear MedicineIsotopeElectronPhotonInflammationProstate cancerX-ray Computed T…Magnetic Resonan…Positron E…

Positron emission tomography (PET) is a three-dimensional imaging technique in nuclear medicine that measures the distribution of a positron-emitting radiopharmaceutical within the body. By selecting a tracer with particular biological properties, PET can reveal processes such as glucose use, tissue perfusion, or binding to a specific molecular target. Unlike imaging methods that primarily depict anatomical structure, PET provides functional and molecular information. It is commonly combined with computed tomography as PET/CT or with magnetic resonance imaging as PET/MRI.

Physical principles

Positron emission and annihilation

A PET radiotracer contains an unstable isotope that undergoes positron-emitting radioactive decay. A positron is the positively charged antiparticle of the electron. After emission, it travels a short distance through tissue, losing energy before interacting with an electron.

This interaction usually produces two annihilation photons, each with an energy of approximately 511 kiloelectronvolts, traveling in nearly opposite directions. Detectors arranged around the patient register pairs of photons arriving within a narrow timing window. Such a pair is called a coincidence event.

The straight line joining the two detecting elements is a line of response. A single event does not ordinarily reveal the exact point at which annihilation occurred, but many events collected from different directions allow a computer to reconstruct the distribution of radioactivity.

The reconstructed distribution is not an exact map of the sites of radioactive decay. Positrons travel before annihilation, and the photons are not perfectly opposed. These effects, together with detector characteristics and counting statistics, limit spatial resolution.

Time-of-flight measurement

Time-of-flight PET uses the small difference between the arrival times of the two photons to estimate where along the line of response an annihilation occurred. The displacement from the line’s midpoint is related to the arrival-time difference by

Δx=c Δt2,\Delta x=\frac{c\,\Delta t}{2},

where cc is the speed of light and Δt\Delta t is the measured timing difference, with the sign depending on the detector convention.

This estimate does not usually pinpoint an individual event precisely. Instead, it narrows the range of likely locations and improves image reconstruction, particularly by reducing image noise.

Radiotracers and what they measure

A PET image reflects the behavior of the selected tracer, not a universal property of disease. Tracer delivery, cellular uptake, binding, chemical transformation, and clearance can all influence the observed signal.

Fluorodeoxyglucose

The most widely used clinical PET tracer is fluorine-18 fluorodeoxyglucose, usually abbreviated FDG or 18F^{18}\mathrm{F}-FDG. It is a glucose analogue transported into cells and phosphorylated by hexokinase. The phosphorylated product is relatively retained in many tissues during the imaging period, making FDG useful for assessing glucose utilization.

Many cancers show increased FDG uptake, but this is not specific to malignancy. Normal brain tissue, variably active heart muscle, exercising skeletal muscle, and sites of inflammation or infection may also accumulate FDG. Activity in the kidneys and urinary tract reflects tracer excretion.

Other tracers

Other radiotracers measure different biological processes:

Tracer or tracer class Principal imaging target or process Examples of use
Rubidium-82 and nitrogen-13 ammonia Myocardial perfusion Assessment of blood supply to heart muscle
Oxygen-15 water Tissue perfusion Quantitative blood-flow studies
Amyloid-binding tracers Fibrillar amyloid deposits Selected evaluations of cognitive impairment
Tau-binding tracers Certain forms and distributions of aggregated tau Selected neurological assessments and research
Somatostatin-receptor tracers Somatostatin receptor expression Imaging of selected neuroendocrine tumors
Prostate-specific membrane antigen tracers PSMA expression Selected applications in prostate cancer
Fluorine-18 sodium fluoride Bone mineral turnover Skeletal imaging in selected settings

Target expression is not always unique to a particular disease. For example, PSMA-tracer uptake can occur in nonprostatic tissues and in some conditions other than prostate cancer.

The radioactive isotope determines the available imaging time and production requirements. Fluorine-18 has a physical half-life of about 110 minutes, permitting regional distribution from production facilities. Carbon-11, nitrogen-13, and oxygen-15 have much shorter half-lives, generally requiring production close to the imaging site. Some isotopes, including rubidium-82 and gallium-68, can be obtained from radionuclide generators.

Image acquisition and reconstruction

Most clinical PET tracers are administered intravenously. Imaging follows an uptake or distribution interval determined by the tracer and the clinical question. The patient lies on a table that moves through a detector ring; coverage may involve a limited region or a larger portion of the body.

Several corrections are necessary to produce interpretable and quantitative images:

  • Attenuation correction: compensates for photons absorbed or scattered out of their original paths before reaching a detector.
  • Scatter correction: estimates events in which a photon changes direction within the body.
  • Random-coincidence correction: accounts for unrelated photons mistakenly registered as a pair.
  • Normalization: corrects for differences in detector response.
  • Decay and count-rate corrections: account for radioactive decay and limitations in recording closely spaced events.

Modern systems commonly use iterative reconstruction methods that model the acquisition process. Reconstruction settings influence noise, apparent lesion size, and measured uptake, so images acquired or processed differently may not be directly comparable.

PET/CT and PET/MRI

PET/CT combines PET with computed tomography. CT supplies anatomical localization and information for attenuation correction. Depending on the examination, the CT component may be a low-dose scan used mainly for localization or a diagnostic-quality examination, sometimes with an intravenous contrast agent.

PET/MRI combines PET with magnetic resonance imaging, offering detailed soft-tissue characterization without the additional ionizing radiation associated with CT. PET/MRI nevertheless involves radiation exposure from the PET tracer. MRI-based attenuation correction presents particular technical challenges because MRI does not directly measure the attenuation of annihilation photons.

Motion between or during acquisitions can cause misregistration. Breathing, for example, may place a lesion in slightly different locations on the PET and CT images.

Clinical applications

Oncology

PET is used in selected cancers for initial evaluation, staging, assessment of treatment response, and investigation of suspected recurrence. It may help identify sites of metastatic disease, select a location for biopsy, or support radiation therapy planning.

FDG PET has established roles in many lymphomas and several solid tumors, including lung cancer. Other malignancies may have low or variable FDG uptake or may be better evaluated with a target-specific tracer.

Metabolic changes can sometimes precede changes in tumor size. However, uptake after treatment may reflect healing, inflammation, or immune activity rather than viable tumor. Interpretation therefore depends on the cancer type, treatment, timing, and other findings. PET does not generally replace histopathological examination when tissue diagnosis is required.

Neurology

Brain FDG PET assesses regional glucose metabolism. Characteristic patterns can contribute to the evaluation of some causes of dementia and to selected presurgical investigations of epilepsy.

Amyloid and tau PET visualize particular protein deposits associated with Alzheimer’s disease. A positive amyloid scan does not, by itself, establish that Alzheimer’s disease is responsible for a person’s symptoms; amyloid deposition can occur without clinical dementia. These scans are interpreted alongside clinical findings and other tests.

Research PET also examines neurotransmitter systems, receptor availability, and drug occupancy, including processes involving dopamine.

Cardiology

Cardiac PET can measure myocardial perfusion and, with suitable acquisition and modeling, quantify myocardial blood flow and flow reserve. These measurements contribute to the assessment of coronary artery disease and coronary microvascular function.

FDG PET can assess myocardial glucose use in selected evaluations of tissue viability. It is also used in selected investigations of inflammatory cardiac disease, where suppression of normal myocardial glucose uptake is important for interpretation.

Infection and inflammation

FDG uptake by activated inflammatory cells supports selected investigations of infection, vascular inflammation, and inflammatory disorders. Because uptake is nonspecific, an abnormal scan does not independently identify the responsible organism or establish a particular inflammatory diagnosis.

Quantification and interpretation

PET can estimate tissue radioactivity concentration. The biological meaning of that measurement depends on the tracer and the acquisition method.

A common semiquantitative measure is the standardized uptake value (SUV). A body-weight-normalized form is

SUV=CtissueAinjected/m,\mathrm{SUV} = \frac{C_{\text{tissue}}} {A_{\text{injected}}/m},

where CtissueC_{\text{tissue}} is tissue activity concentration, AinjectedA_{\text{injected}} is administered activity corrected to the appropriate reference time, and mm is body mass. Compatible units and correction for residual activity are necessary. Other normalization methods use lean body mass or body surface area.

SUV is not an intrinsic constant of a lesion. It varies with uptake time, blood glucose, body composition, scanner calibration, reconstruction, motion, and lesion size. A universal SUV threshold cannot reliably distinguish benign from malignant tissue.

Dynamic PET records changes in tracer concentration over time. Combined with a blood input function and appropriate kinetic models, it can estimate quantities such as metabolic rates, blood flow, or receptor-binding parameters. This approach is more demanding than a conventional static scan and is used in specialized clinical settings and research.

Limitations and safety

Diagnostic limitations

PET has finite spatial resolution, commonly on the order of a few millimeters in clinical systems. Small lesions may be missed or have underestimated uptake because their signal is spread across surrounding image elements, an effect known as the partial-volume effect.

False-positive findings can result from physiological uptake, inflammation, infection, or treatment-related changes. False-negative findings can occur with small lesions, low tracer avidity, high surrounding background activity, or technical problems. Sensitivity and specificity consequently vary by tracer, disease, anatomical site, and clinical setting.

PET findings are interpreted with anatomical imaging, clinical history, laboratory results, and, where relevant, tissue examination. Uptake alone does not establish a diagnosis.

Radiation and procedural considerations

PET exposes the patient to ionizing radiation from the radiotracer; PET/CT adds exposure from CT. The total dose depends on the tracer, administered activity, equipment, body characteristics, and CT protocol. Diagnostic PET tracer quantities are generally too small to produce the pharmacological effects associated with therapeutic drug doses.

Pregnancy and breastfeeding require tracer-specific assessment because radioactive material may expose the fetus or enter breast milk. If CT contrast is used, its risks are separate from those of the PET radiotracer. PET/MRI also carries the usual MRI-related considerations, including compatibility with implanted devices.

Development and related techniques

PET developed from mid-twentieth-century work on positron coincidence detection and emission imaging. Tomographic scanners and computational reconstruction advanced during the 1970s, alongside the development of practical radiotracers such as FDG. Later developments included improved scintillation detectors, iterative reconstruction, hybrid PET/CT and PET/MRI, and increasingly precise timing measurements.

PET differs from single-photon emission computed tomography (SPECT), which detects individual gamma photons and generally uses physical collimators to determine their direction. PET instead uses paired annihilation photons and electronic coincidence detection. Their radionuclides, instrumentation, resolution, quantification methods, and clinical uses differ.

Long-axial-field-of-view and total-body PET systems extend detector coverage over much more of the body at once. Their increased sensitivity can support shorter acquisitions, lower administered activity in suitable protocols, and simultaneous study of tracer kinetics across multiple organs. Availability, cost, data volume, and protocol standardization remain practical constraints.